Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel

Blood (2024) 143 (9): 822–832.

https://doi.org/10.1182/blood.2023022348

Published: 2024

Includes: Supplemental data

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

Carlo Gambacorti-Passerini, MD, Alberto Alvarez-Larrán, MD, Sarit E Assouline, MD MSc, Patrizia Pregno, Philipp D le Coutre, MD, Susanne Saussele, MD, Laura Antolini, PhD, Brian J. Druker, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-140234

Published: 2020

Journal Articles

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Samantha Worme, BSc, Selin Jessa, BSc, William Poon, BSc, Maja Jankovic, MSc, Gabriela Galicia Vazquez, PhD, Alexandre Bazinet, MD, Katharine Fooks, BSc, Isabella Iasenza, BSc, Patricia Arreba-Tutusaus, PhD, Kolja Eppert, PhD, Ioannis Ragoussis, PhD, Yu Chang Wang, PhD, Nathalie A Johnson, MD PhD, Sarit E Assouline, MD MSc, Claudia L Kleinman, PhD, François E Mercier, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143221

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135818

Published: 2020

Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-137245

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-135839

Published: 2020

Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136109

Published: 2020

Journal Articles

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Adi J. Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Alexa Del Corpo, Michaël Harnois, MSc, Michel-Olivier Gratton, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Luigina Mollica, MD PhD, Pierre Laneuville, MD FRCPC, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2016) 128 (22): 3072.

https://doi.org/10.1182/blood.V128.22.3072.3072

Published: 2016

Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Blood (2016) 128 (22): 1218.

https://doi.org/10.1182/blood.V128.22.1218.1218

Published: 2016

Journal Articles

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Blood (2016) 128 (2): 185–194.

https://doi.org/10.1182/blood-2016-02-699520

Published: 2016

Includes: Supplemental data

Journal Articles

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

David Cunningham, Pier Luigi Zinzani, MD PhD, Sarit E. Assouline, MDMSc, Krimo Bouabdallah, MD, Dominique Bron, MD PhD, Corinne Haioun, MD PhD, Luigina Mollica, MD FRCPC, PhD, Marius Giurescu, MDPhD, Igor Gorbatchevsky, MD, Manoel Neves, MD, Marta M. Lemos, MD, Julia Grunert, PhD, Florian Hiemeyer, PhD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 3935.

https://doi.org/10.1182/blood.V126.23.3935.3935

Published: 2015

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Blood (2015) 126 (23): 2775.

https://doi.org/10.1182/blood.V126.23.2775.2775

Published: 2015

Journal Articles

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Adi J Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Michel-Olivier Gratton, MSc, Michaël Harnois, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Luigina Mollica, MD FRCPC, PhD, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc

Blood (2015) 126 (23): 2778.

https://doi.org/10.1182/blood.V126.23.2778.2778

Published: 2015

NARROW

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only